<![CDATA[Background. Systemic Lupus Erythematosus (SLE) is an autoimmunedisease with multisystem involvement which arises from multifactorialcauses. Continuous exposure to autoantigens and chronic activation of theimmune system, especially memory T lymphocytes, contribute to prematureimmunosenescence. sCTLA-4 and sCD86 are soluble costimulatorymolecules of CTLA-4 and CD86, which play a role in the occurrence ofimmunosenescence in SLE. The presence of immunosenescence will causehigher morbidity and mortality. This research was conducted to establishthe correlation between the increased levels of sCTLA-4 and sCD86 and theseverity of SLE, as measured by the SLE Disease Activity Index (SLEDAI)score. Methods. This analytical observational research utilized a crosssectional approach involving 35 female SLE patients diagnosed according to the SLICC 2012 criteria. SLE disease activity was measured using SLEDAI score. Serum sCTLA-4 and sCD86 levels were measured using the ELISA method. Statistical analysis was conducted using the Mann-Whitney test for comparisons and the Spearman test for correlation analysis, with a significance level of p<0.05. Results. sCTLA-4 levels were higher and significantly different in patients with moderate SLE (p=<0.001; p<0.05), and there was no significant difference in sCD86 levels (p=0.915; p>0.05).Increased sCTLA-4 levels were positively correlated with the severity of SLE(r =0.361, p=0.033), while no significant correlation was observed in sCD86levels (r=-0.094, p=0.591). Conclusion. Elevated sCTLA-4 levels werepositively correlated with increased severity of SLE based on the SLEDAIscore. ]]>
